SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Hsing AW, Tsao L, Devesa SS. International trends and patterns of prostate cancer incidence and mortality. Int J Cancer 2000; 85: 607
  • 2
    Scardino PT, Wheeler TM. Local control of prostate cancer with radiotherapy: frequency and prognostic significance of positive results of postirradiation prostate biopsy. NCI Monograph 1988: 95103
  • 3
    Crook JM, Perry GA, Robertson S, Esche BA. Routine prostate biopsies following radiotherapy for prostate cancer: results for 226 patients. Urology 1995; 45: 62431
  • 4
    Zelefsky MJ, Leibel SA, Gaudin PB et al. Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys 1998; 41: 491500
  • 5
    Radford IR. Evidence for a general relationship between the induced level of DNA double-strand breakage and cell-killing after X-irradiation of mammalian cells. Int J Radiat Biol Relat Stud Phys Chem Med 1986; 49: 61120
  • 6
    Ward JF. The complexity of DNA damage: relevance to biological consequences. Int J Radiat Biol 1994; 66: 42732
  • 7
    Tauchi H, Sawada S. Analysis of mitotic cell death caused by radiation in mouse leukaemia L5178Y cells: apoptosis is the ultimate form of cell death following mitotic failure. Int J Radiat Biol 1994; 65: 44955
  • 8
    Haimovitz-Friedman A, Kolesnick RN, Fuks Z. Modulation of the apoptotic response. Potential for improving the outcome in clinical radiotherapy. Semin Radiat Oncol 1996; 6: 27383
  • 9
    Montpetit ML, Lawless KR, Tenniswood M. Androgen-repressed messages in the rat ventral prostate. Prostate 1986; 8: 2536
  • 10
    Sensibar JA, Sutkowski DM, Raffo A et al. Prevention of cell death induced by tumour necrosis factor alpha in LNCaP cells by overexpression of sulfated glycoprotein-2 (clusterin). Cancer Res 1995; 55: 24317
  • 11
    Connor J, Buttyan R, Olsson CA, D’Agati V, O'Toole K, Sawczuk IS. SGP-2 expression as a genetic marker of progressive cellular pathology in experimental hydronephrosis. Kidney Int 1991; 39: 1098103
  • 12
    Kyprianou N, English HF, Davidson NE, Isaacs JT. Programmed cell death during regression of the MCF-7 human breast cancer following estrogen ablation. Cancer Res 1991; 51: 1626
  • 13
    May PC, Lampert-Etchells M, Johnson SA, Poirier J, Masters JN, Finch CE. Dynamics of gene expression for a hippocampal glycoprotein elevated in Alzheimer's disease and in response to experimental lesions in rat. Neuron 1990; 5: 8319
  • 14
    Wunsche W, Tenniswood MP, Schneider MR, Vollmer G. Estrogenic regulation of clusterin mRNA in normal and malignant endometrial tissue. Int J Cancer 1998; 76: 6848
  • 15
    Humphreys DT, Carver JA, Easterbrook-Smith SB, Wilson MR. Clusterin has chaperone-like activity similar to that of small heat shock proteins. J Biol Chem 1999; 274: 687581
  • 16
    Hatters DM, Wilson MR, Easterbrook-Smith SB, Howlett GJ. Suppression of apolipoprotein C-II amyloid formation by the extracellular chaperone, clusterin. Eur J Biochem 2002; 269: 278994
  • 17
    Poon S, Treweek TM, Wilson MR, Easterbrook-Smith SB, Carver JA. Clusterin is an extracellular chaperone that specifically interacts with slowly aggregating proteins on their off-folding pathway. FEBS Lett 2002; 513: 259 66
  • 18
    Bettuzzi S, Scorcioni F, Astancolle S, Davalli P, Scaltriti M, Corti A. Clusterin (SGP-2) transient overexpression decreases proliferation rate of SV40-immortalized human prostate epithelial cells by slowing down cell cycle progression. Oncogene 2002; 21: 432834
  • 19
    Miyake H, Nelson C, Rennie PS, Gleave ME. Testosterone-repressed prostate message-2 is an antiapoptotic gene involved in progression to androgen independence in prostate cancer. Cancer Res 2000; 60: 1706
  • 20
    Miyake H, Nelson C, Rennie PS, Gleave ME. Acquisition of chemoresistant phenotype by overexpression of the antiapoptotic gene testosterone-repressed prostate message-2 in prostate cancer xenograft models. Cancer Res 2000; 60: 254754
  • 21
    Zellweger T, Chi K, Miyake H et al. Enhanced radiation sensitivity in prostate cancer by inhibition of the cell survival protein clusterin. Clin Cancer Res 2002; 8: 327684
  • 22
    Leith JT. In vitro radiation sensitivity of the LNCaP prostatic tumour cell line. Prostate 1994; 24: 11924
  • 23
    Miyake H, Hanada N, Nakamura H et al. Overexpression of Bcl-2 in bladder cancer cells inhibits apoptosis induced by cisplatin and adenoviral-mediated p53 gene transfer. Oncogene 1998; 16: 93343
  • 24
    Donnellan R, Chetty R. Cyclin D1 and human neoplasia. Mol Pathol 1998; 51: 17
  • 25
    Kyprianou N, King ED, Bradbury D, Rhee JG. bcl-2 over-expression delays radiation-induced apoptosis without affecting the clonogenic survival of human prostate cancer cells. Int J Cancer 1997; 70: 3418
  • 26
    Scherr DS, Vaughan ED Jr, Wei J et al. BCL-2 and p53 expression in clinically localized prostate cancer predicts response to external beam radiotherapy. J Urol 1999; 162: 126
  • 27
    Mackey TJ, Borkowski A, Amin P, Jacobs SC, Kyprianou N. bcl-2/bax ratio as a predictive marker for therapeutic response to radiotherapy in patients with prostate cancer. Urology 1998; 52: 108590
  • 28
    Szostak MJ, Kaur P, Amin P, Jacobs SC, Kyprianou N. Apoptosis and bcl-2 expression in prostate cancer: significance in clinical outcome after brachytherapy. J Urol 2001; 165: 212630
  • 29
    Yang CR, Leskov K, Hosley-Eberlein K et al. Nuclear clusterin/XIP8, an x-ray-induced Ku70-binding protein that signals cell death. Proc Natl Acad Sci USA 2000; 97: 590712
  • 30
    Miyake H, Chi KN, Gleave ME. Antisense TRPM-2 oligodeoxynucleotides chemosensitize human androgen-independent PC-3 prostate cancer cells both in vitro and in vivo. Clin Cancer Res 2000; 6: 165563
  • 31
    Zellweger T, Miyake H, July LV, Akbari M, Kiyama S, Gleave ME. Chemosensitization of human renal cell cancer using antisense oligonucleotides targeting the antiapoptotic gene clusterin. Neoplasia 2001; 3: 3607
  • 32
    Zellweger T, Miyake H, Cooper S et al. Antitumour activity of antisense clusterin oligonucleotides is improved in vitro and in vivo by incorporation of 2′-O-(2-methoxy)ethyl chemistry. J Pharmacol Exp Ther 2001; 298: 93440
  • 33
    Boise LH, Gonzalez-Garcia M, Postema CE et al. bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell 1993; 74: 597608
  • 34
    Rouayrenc JF, Boise LH, Thompson CB, Privat A, Patey G. Presence of the long and the short forms of Bcl-X in several human and murine tissues. C R Acad Sci III 1995; 318: 53740
  • 35
    Minn AJ, Boise LH, Thompson CB. Bcl-x (S) antagonizes the protective effects of Bcl-x (L). J Biol Chem 1996; 271: 630612
  • 36
    Wong P, Pineault J, Lakins J et al. Genomic organization and expression of the rat TRPM-2 (clusterin) gene, a gene implicated in apoptosis. J Biol Chem 1993; 268: 502131
  • 37
    Lakins J, Bennett SA, Chen JH et al. Clusterin biogenesis is altered during apoptosis in the regressing rat ventral prostate. J Biol Chem 1998; 273: 2788795